News >

Wnt Pathway Emerges as Attractive Target in CRC

Caroline Seymour
Published: Monday, Nov 04, 2019

Lukas E. Dow, PhD,an assistant professor of biochemistry and medicine at Weill Cornell Medicine

Lukas E. Dow, PhD

Wnt could be a prime target and immune agonist in colorectal cancer (CRC), given that the protein is present in the majority of patients with the disease. However, investigators are still in the early stages of identifying and developing compounds capable of targeting mutations that activate the pathway, said Lukas E. Dow, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication